Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma
Pierre Stéphan(Boston University), Jennifer L. Crombie(Dana-Farber Cancer Institute), Robert Redd(Harvard University), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), Boyu Hu(University of Utah), Alex F. Herrera(City of Hope), Steven M. Bair(University of Colorado Cancer Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Allison M. Bock(Mayo Clinic), Alexey Danilov(City of Hope), Philippe Armand(Harvard University), Karan Chohan(The University of Texas MD Anderson Cancer Center), Amy Ayers(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Ajay Major(University of Colorado Cancer Center), Shannon M. Buckley(University of Utah), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Gilles Salles(Memorial Sloan Kettering Cancer Center), Sonia Godbole(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Matthew A. Lunning(University of Nebraska Medical Center), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Andrew Jallouk(Vanderbilt University Medical Center), Swetha Kambhampati(City Of Hope National Medical Center), Geoffrey Shouse(City Of Hope National Medical Center)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603